Common shares
- Symbol
- ABCL
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 7.01, 9.01 · 8-K
AbCellera Biologics Inc.
ABCLNASDAQEQUITYCurrent
Results of Operations and Financial Condition · Regulation FD Disclosure
Item 2.02 Results of Operations and Financial Condition On August 5, 2026, AbCellera Biologics Inc. (the “Company”), issued a press release announcing its financial and operational results for the quarter ended June 30, 2026. A copy of the press release is furnished herewith as Exhibit 99.1.
Press release in this filing
Q2 2026 Business Summary and Program Updates →Company context
AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the areas of endocrinology, women’s health, immunology, oncology, and more.
Current securities
Registered securities in this filing
AbCellera Biologics Inc. · 8-K · Filed 2026-08-05
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition
On August 5, 2026, AbCellera Biologics Inc. (the “Company”), issued a press release announcing its financial and operational results for the quarter ended June 30, 2026. A copy of the press release is furnished herewith as Exhibit 99.1.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD
In connection with its earnings call on August 5, 2026, to discuss its results for the quarter ended June 30, 2026, the Company will utilize a corporate presentation, a copy of which is furnished herewith as Exhibit 99.2.
The information in Items 2.02 and 7.01 of this Form 8-K (including the exhibits attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.